|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.72 USD | +1.39% |
|
+3.40% | +17.12% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 33.3 | +62.93% | 12 | ||||||
| 820.72 | +23.52% | 27 | ||||||
| 287.95 | +22.17% | 19 | ||||||
| 2,052,158.8 | +48.38% | 24 | ||||||
| 96.64 | +13.41% | 16 | ||||||
| 225.45 | +14.3% | 31 | ||||||
| 48.26 | -29.32% | 19 | ||||||
| 113.82 | -1.11% | 22 | ||||||
| 101.47 | +21.05% | 25 | ||||||
| 486.67 | +6.73% | 12 | ||||||
| 104.7 | +26.66% | 22 | ||||||
| 280.39 | +18.04% | 20 | ||||||
| 87.69 | +48.76% | 26 | ||||||
| 458,000 | +58.75% | 5 | ||||||
| 361.67 | +3.26% | 9 | ||||||
| - | - | 61.5 | +14.35% | 1 | ||||
| 14.4 | +59.6% | 12 | ||||||
| 72.5 | +4.03% | 2 | ||||||
| 30.05 | +91.72% | 9 | ||||||
| 85.5 | -7.68% | 10 | ||||||
| Average | 125,673.57 | +24.98% | 16 | ||||||
| Weighted average by Cap. | 224,925.8 | +20.53% | 20 |
- Stock Market
- Stocks
- ZLAB Stock
- Sector Zai Lab Limited
- Sector consensus
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
